"Viking Therapeutics' Weight Loss Drug Sends Shares Soaring: Is It a Buy Now?"

Viking Therapeutics' shares surged 120% after positive data from a phase 2 trial of its weight loss candidate, sparking investor optimism about its potential entry into the market or attracting a buyer. The company specializes in developing therapeutics for metabolic and endocrine disorders and is studying four candidates in trials. Despite the promising results, it may be too late to buy the stock after the rapid gain, as the candidate still needs to go through pivotal trials and compete with big pharma companies with significant market share. However, a potential buyout or sustained progress could make it a consideration in the future.